Durvalumab-Induced Hyperprogressive Disease in Nonmetastatic Lung Cancer

J Oncol Pract. 2019 Apr;15(4):217-219. doi: 10.1200/JOP.18.00739. Epub 2019 Mar 18.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / pharmacology
  • Antineoplastic Agents, Immunological / adverse effects*
  • Antineoplastic Agents, Immunological / pharmacology
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Middle Aged

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents, Immunological
  • durvalumab